Part VI: Summary of the Risk Management Plan

Summary of Risk Management Plan for IRINOTECAN 20 mg/mL concentrate for solution for infusion

This is a summary of the risk management plan (RMP) for IRINOTECAN 20 mg/mL concentrate for solution for infusion (hereinafter referred to as Irinotecan). The RMP details important risks of Irinotecan, how these risks can be minimised, and how more information will be obtained about product's risks and uncertainties (missing information).

Irinotecan's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Irinotecan should be used.

Important new concerns or changes to the current ones will be included in updates of Irinotecan's RMP.

I. The Medicine and What It is used for

Irinotecan is authorised for the treatment of patients with advanced colorectal cancer:

- In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease
- As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen

In combination with cetuximab, irinotecan hydrochloride trihydrate is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy.

In combination with 5-fluorouracil, folinic acid and bevacizumab, irinotecan hydrochloride trihydrate is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

In combination with capecitabine, irinotecan hydrochloride trihydrate is indicated for the first-line treatment of patients with metastatic colorectal carcinoma.

It contains Irinotecan as the active substance and it is given intravenously.

II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks

Important risks of Irinotecan, together with measures to minimise such risks and the proposed studies for learning more about Irinotecan's risks, if any, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;

- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of Important Risks and Missing Information

Important risks of Irinotecan are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Irinotecan. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 1: Summary of Safety Concerns

Summary of safety concerns	
Important identified risks	• None
Important potential risks	• None
Missing information	• None

II.B Summary of Important Risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-Authorisation Development Plan

II.C.1 Studies Which Are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Irinotecan.

II.C.2 Other Studies in Post-Authorisation Development Plan

There are no studies required for Irinotecan.